DRAGON

Bell Media Brings Crave to Prime Video Channels in Canada

Retrieved on: 
Tuesday, February 6, 2024

TORONTO, Feb. 6, 2024 /CNW/ - Bell Media announced today that it has reached an agreement with Amazon to make its best-in-class streaming service, Crave, available on Prime Video Channels in Canada.

Key Points: 
  • TORONTO, Feb. 6, 2024 /CNW/ - Bell Media announced today that it has reached an agreement with Amazon to make its best-in-class streaming service, Crave, available on Prime Video Channels in Canada.
  • Launching soon, Crave's Premium, ad-free plan will be offered directly to Amazon customers through their Prime Video account.
  • "We're thrilled to be joining with Amazon to expand the reach of Crave," said Sean Cohan, President, Bell Media.
  • "Making Crave available to as many Canadians as possible, on the service and device of their choosing, is a top priority for Bell Media."

Scholar Rock Provides Corporate Update and Highlights Priorities for 2024

Retrieved on: 
Thursday, January 4, 2024

Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy (SMA), cardiometabolic disorders, and other serious diseases where protein growth factors play a fundamental role, today provided recent corporate updates and highlighted upcoming priorities for 2024.

Key Points: 
  • Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy (SMA), cardiometabolic disorders, and other serious diseases where protein growth factors play a fundamental role, today provided recent corporate updates and highlighted upcoming priorities for 2024.
  • Planning to announce Phase 3 SAPPHIRE clinical trial topline data in 4Q 2024.
  • Scholar Rock management will highlight these updates in a corporate presentation at the 42nd Annual J.P. Morgan Healthcare Conference on Tuesday, January 9, 2024, at 1:30 p.m. PT (4:30 p.m.
  • A live webcast of the presentation may be accessed by visiting the Investors & Media section of the Scholar Rock website at http://investors.scholarrock.com .

Mouser Electronics Named High Service Distributor of the Year by KYOCERA AVX for Best-in-Class Performance

Retrieved on: 
Thursday, December 21, 2023

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20231221435881/en/
    Representatives from KYOCERA AVX present the Mouser team with the High Service North American Distributor of the Year Award.
  • "On behalf of the entire Mouser team, we want to express our sincere gratitude to KYOCERA AVX for this recognition.
  • To learn more about KYOCERA AVX and its extensive product line available from Mouser, please visit https://www.mouser.com/manufacturer/kyocera-avx/ .
  • As a global authorized distributor, Mouser offers the widest selection of the newest semiconductors, electronic components and industrial automation products.

Belite Bio Reports Third Quarter 2023 Operational Highlights and Financial Results

Retrieved on: 
Tuesday, November 14, 2023

ET

Key Points: 
  • ET
    SAN DIEGO, Nov. 13, 2023 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE) (“Belite” or the “Company”), a clinical-stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today announced its financial results for the three-months ended September 30, 2023, and provided a general business update.
  • “We made meaningful progress in the quarter advancing our clinical trials for Tinlarebant and are excited by our results,” said Dr. Tom Lin, Chairman and CEO of Belite Bio.
  • Third Quarter 2023 Financial Results:
    Cash: As of September 30, 2023, the Company had $54.5 million in cash.
  • Belite Bio will host a webcast on Tuesday, November 14, 2023, at 4:30 p.m. Eastern Time to discuss the Company’s financial results and provide a business update.

Templeton Dragon Fund, Inc. Announces Self Tender Offer for up to 25% of Its Shares

Retrieved on: 
Tuesday, November 14, 2023

If more shares are tendered than the amount the Board has authorized to purchase, the Fund will purchase a number of shares equal to the offer amount on a pro-rated basis.

Key Points: 
  • If more shares are tendered than the amount the Board has authorized to purchase, the Fund will purchase a number of shares equal to the offer amount on a pro-rated basis.
  • The commencement of the tender offer is pursuant to an agreement between the Fund and City of London Investment Management Company Limited (“CoL”).
  • The Fund’s common shares have recently traded at a discount to their net asset value per share.
  • Franklin Resources, Inc. is a global investment management organization with subsidiaries operating as Franklin Templeton and serving clients in over 150 countries.

Space Force selects GURU and Princeton to Build the Future of Immersive Collaborative Training for Space Flight Operations

Retrieved on: 
Monday, December 18, 2023

GURU will bring autonomy to simulation and visualization workloads to meet demand coming from the worldwide radical increase in space missions.

Key Points: 
  • GURU will bring autonomy to simulation and visualization workloads to meet demand coming from the worldwide radical increase in space missions.
  • The volume of both commercial and government space missions is growing exponentially, and teaching trainers with varying amounts of experience to create effective space flight mission operations training scenarios is a challenging task that requires careful planning and adaptation.
  • This effort requires the integration of a variety of simulation software packages critical to space flight, including open source and commercial software like GMAT and Cesium.
  • The commercialization opportunity from just the Unreal Engine component of this work addresses several million worldwide users, and commercial space demands this level of autonomy as space flight operations become as routine as commercial airline traffic.

Scholar Rock Reports Third Quarter 2023 Financial Results and Highlights Business Progress

Retrieved on: 
Tuesday, November 7, 2023

The Company announced that it completed enrollment in September 2023, with topline data expected in the fourth quarter of 2024.

Key Points: 
  • The Company announced that it completed enrollment in September 2023, with topline data expected in the fourth quarter of 2024.
  • Research and development expense was $30.3 million for the quarter ended September 30, 2023, compared to $33.4 million for the quarter ended September 30, 2022.
  • General and administrative expense was $13.3 million for the quarter ended September 30, 2023, compared to $10.5 million for the quarter ended September 30, 2022.
  • A live webcast of the conference call will be available on the Investors & Media section of the Scholar Rock website at http://investors.scholarrock.com .

Belite Bio Presents Results from a 24-month, Phase 2 Study of Tinlarebant in Childhood-onset Stargardt Disease at the AAO Annual Meeting

Retrieved on: 
Monday, November 6, 2023

“Tinlarebant’s final Phase 2 results represent a significant milestone for Belite Bio and provide additional foundational support for the work being conducted across our trials,” said Dr. Tom Lin, Chairman and CEO of Belite Bio.

Key Points: 
  • “Tinlarebant’s final Phase 2 results represent a significant milestone for Belite Bio and provide additional foundational support for the work being conducted across our trials,” said Dr. Tom Lin, Chairman and CEO of Belite Bio.
  • “We are very encouraged by the promising 24-month treatment final results from this Phase 2 study.
  • The Natural History of the Progression of Atrophy Secondary to Stargardt Disease (ProgStar) Studies: Design and Baseline Characteristics: ProgStar Report No.
  • Progression of Stargardt Disease as Determined by Fundus Autofluorescence in the Retrospective Progression of Stargardt Disease Study (ProgStar Report No.

Scholar Rock Presents New Data from Phase 1 DRAGON Trial Showing Promising Anti-Tumor Activity in Anti-PD-1 Resistant Metastatic ccRCC Patients and Supporting SRK-181 Continued Tolerability

Retrieved on: 
Friday, November 3, 2023

The second poster focuses on preliminary biomarker data from part B of the trial in patients with multiple tumor types.

Key Points: 
  • The second poster focuses on preliminary biomarker data from part B of the trial in patients with multiple tumor types.
  • Data presented continues to support proof of concept for SRK-181 in 28 heavily pretreated patients with ccRCC resistant to anti-PD-1.
  • In the biomarker analysis for ccRCC, levels of circulating granulocytic myeloid-derived suppressor cells (gMDSC) correlated with clinical activity in ccRCC patients treated with SRK-181 in combination with pembrolizumab.
  • “The DRAGON trial has successfully delivered on its objective of demonstrating proof of concept for SRK-181 by showing promising anti-tumor activity.

Scholar Rock to Present Clinical and Biomarker Data from the Phase 1 DRAGON Trial at the SITC 38th Annual Meeting

Retrieved on: 
Thursday, October 19, 2023

Scholar Rock (NASDAQ: SRRK), a Phase 3 clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, announced today that it will present data from DRAGON, a Phase 1 study of SRK-181 in patients with advanced solid tumors at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting in San Diego on November 1-5.

Key Points: 
  • Scholar Rock (NASDAQ: SRRK), a Phase 3 clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, announced today that it will present data from DRAGON, a Phase 1 study of SRK-181 in patients with advanced solid tumors at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting in San Diego on November 1-5.
  • In one poster presentation, Scholar Rock will share preliminary biomarker data from Part B of the trial, and in a second poster presentation, provide safety, efficacy, and biomarker results of SRK-181 in anti-PD-1 resistant metastatic clear cell renal cell carcinoma (ccRCC) patients from both Parts A and B.
  • “We are excited to present clinical and biomarker updates on the DRAGON study, which build upon the safety and efficacy data to date in the ccRCC cohort of the trial and support our goal of establishing the proof of mechanism of SRK-181,” said Jay Backstrom, M.D., MPH, President and Chief Executive Officer of Scholar Rock.
  • “As a selective latent TGFβ1 inhibitor, SRK-181 has the potential to transform cancer immunotherapy by helping to overcome resistance to checkpoint inhibitor therapy.